Clinical Laserthermia Systems and Toronto General Hospital Begin Clinical Study for MRI-Guided Laser Ablation Treatment of Prostate Cancer
Framingham, MA – April 17, 2018- Clinical Laserthermia Systems Americas, Inc. (CLS) a subsidiary of CLS AB in Lund, Sweden, today announced the commencement of a clinical study with Toronto General Hospital in Canada investigating MRI-guided, focal laser ablation (FLA) treatments for prostate cancer. The study has been approved by Health Canada and its results will be published on the National Institute of Health Web site:www.clinicaltrials.gov.
Starting in April 2018, twenty-five patients will participate in a 24-month study at the hospital to evaluate the safety and efficacy of CLS’s TRANBERG®|Thermal Therapy Systemand single-use accessories. The study includes men with early stage prostate cancer that have not already undergone radiation or hormone treatment.
“We are very pleased Toronto General Hospital has chosen our minimally invasive TRANBERG Thermal Therapy System for this important clinical study,” stated Lars-Erik Eriksson, CEO of Clinical Laserthermia Systems AB. “The study will produce important data surrounding the performance and efficacy of the TRANBERG Thermal Therapy System for MRI guided focal laser ablation treatments.”
Unique, Non-Cooled, Diffusing Fiber Technology
CLS utilizes unique, non-cooled, diffusing laser fiber technology to optimize heat distribution in tissue while eliminating the need for external cooling. The system also includes features designed to improve workflow and reduce procedure times.
The TRANBERG®|Thermal Therapy System has not yet received market clearance for immune stimulating interstitial laser thermotherapy (imILT®) by the Food and Drug Administration (FDA) in the United States of America (USA).
CLS Americas, Inc.
Alan Weinberg, General Manager
P: (508) 620-4521
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immunostimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and have subsidiaries in Berlin, Germany and Boston, MA,USA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on the company’s website: www.clinicallaser.se